Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
November 20, 2025JAMA Network OpenOpen Access

Nirsevimab Prophylaxis and Respiratory Syncytial Virus Hospitalizations Among Infants

View Full Paper
Ask AI
Bookmark
Share

Authors

ECEnrico CocchiSBSilvia BloiseALAurora Lorefice

Discussion

Loading...

Member takes

Overview

Multicenter cohort study demonstrates reduced RSV hospitalization in high-risk infants with nirsevimab prophylaxis, highlighting ongoing risks.

Key Points

  • To assess the impact of nirsevimab prophylaxis on RSV hospitalization risk and severity in infants.
  • Retrospective multicenter cohort study across 5 neonatal hospitals
  • Participants included all live births with no gestational age exclusions
  • Follow-up until first RSV hospitalization or one year of age
  • Data included demographics, nirsevimab administration, and confirmed RSV cases
  • Utilized hierarchical Cox proportional hazards regression models for analysis.
  • Nirsevimab prophylaxis achieved 79.2% coverage among 13,624 newborns
  • Post-nirsevimab season had significantly fewer RSV LRTI hospitalizations (72 vs 220; P < .001)
  • Nirsevimab associated with a reduced hazard of RSV hospitalization (HR, 0.32; 95% CI, 0.25-0.44; P < .001)
  • Prematurity and having older siblings were linked to higher hospitalization risk even with prophylaxis
  • Nirsevimab reduced HFNC use but not hospital stay duration.

Cite This Study

Cocchi et al. (2025) studied this question.

synapsesocial.com/papers/6924f07fc0ce034ddc3501c5https://doi.org/10.1001/jamanetworkopen.2025.44679
View Full Paper
Ask AI
Bookmark
Share